Published in Alzheimer Dis Assoc Disord on June 09, 2003
American Indians/Alaska natives and dementia. Alzheimer Dis Assoc Disord (2002) 1.47
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA (2008) 7.35
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial. Br J Psychiatry (2010) 3.72
Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology (2011) 2.43
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Translational research in neurology and neuroscience 2010-2011. Arch Neurol (2010) 1.96
Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol (2005) 1.91
Risk factors for potentially harmful informal caregiver behavior. J Am Geriatr Soc (2005) 1.81
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol (2004) 1.78
Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol (2007) 1.75
Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci (2002) 1.69
Translating biomedical research to the bedside: a national crisis and a call to action. JAMA (2003) 1.63
Performance of elderly Native Americans and Caucasians on the CERAD Neuropsychological Battery. Alzheimer Dis Assoc Disord (2005) 1.60
Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study. Mayo Clin Proc (2011) 1.43
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement (2008) 1.39
Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry (2008) 1.39
Genome-wide association studies in Alzheimer disease. Arch Neurol (2008) 1.38
Feasibility of telecognitive assessment in dementia. Assessment (2006) 1.30
Patterns of verbal memory performance in mild cognitive impairment, Alzheimer disease, and normal aging. Cogn Behav Neurol (2006) 1.28
Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment. J Mol Neurosci (2003) 1.22
The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study. Ann Intern Med (2013) 1.21
Insight and frontal cortical function in schizophrenia: a review. Schizophr Res (2006) 1.18
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci (2007) 1.17
Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimers Dement (2006) 1.16
FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer's disease. Eur Radiol (2005) 1.09
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol (2003) 1.07
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA (2009) 1.07
Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci (2005) 1.06
Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci (2006) 1.05
Vascular disease and risk factors, rate of progression, and survival in Alzheimer's disease. J Geriatr Psychiatry Neurol (2006) 1.03
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol (2011) 1.02
Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil. J Speech Lang Hear Res (2004) 1.02
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol (2011) 1.01
White matter hyperintensities: use of aortic arch pulse wave velocity to predict volume independent of other cardiovascular risk factors. Radiology (2013) 1.01
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine (2010) 1.00
Psychometric evaluation of the Montreal Cognitive Assessment (MoCA) in three diverse samples. Clin Neuropsychol (2010) 0.99
Altered neural cholinergic receptor systems in cocaine-addicted subjects. Neuropsychopharmacology (2010) 0.99
Advances in the development of vaccines for Alzheimer's disease. Discov Med (2013) 0.97
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. J Neuroimmunol (2012) 0.94
Emergent psychopathology in Alzheimer's disease patients over 12 months associated with functional, not cognitive, changes. J Geriatr Psychiatry Neurol (2002) 0.94
Can alzheimer's disease and dementias with Lewy bodies be distinguished clinically? J Geriatr Psychiatry Neurol (2003) 0.93
Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. J Neuropsychiatry Clin Neurosci (2005) 0.92
Can a direct IADL measure detect deficits in persons with MCI? Curr Alzheimer Res (2009) 0.92
ADCS Prevention Instrument Project: quality of life assessment (QOL). Alzheimer Dis Assoc Disord (2006) 0.92
Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis (2012) 0.90
Comparison of functional and cognitive donepezil effects in Alzheimer's disease. Int Psychogeriatr (2002) 0.88
Cross-cultural adaptation and psychometric validation of a Spanish version of the Quality of Life in Late-Stage Dementia Scale. Qual Life Res (2010) 0.87
Cognitive endophenotypes of psychosis within dimension and diagnosis. Psychiatry Res (2012) 0.87
Three-word recall in normal aging. J Clin Exp Neuropsychol (2004) 0.86
Treat Alzheimer disease before it is symptomatic. Arch Neurol (2011) 0.85
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84
Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease. Transl Neurosci (2012) 0.83
Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease. J Neuropsychiatry Clin Neurosci (2002) 0.83
Prion proteins: physiological functions and role in neurological disorders. J Neurol Sci (2007) 0.83
Leptin and cognition. Dement Geriatr Cogn Disord (2012) 0.83
An Abbreviated Montreal Cognitive Assessment (MoCA) for Dementia Screening. Clin Neuropsychol (2015) 0.83
Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia. Dement Geriatr Cogn Disord (2004) 0.82
A randomized, controlled study of an Alzheimer's caregiver skills training program. Am J Alzheimers Dis Other Demen (2005) 0.82
Dementia diagnosis, treatment, and research with American Indians. Alzheimers Dement (2006) 0.82
Comparison of Alzheimer's disease in Native Americans and Whites. Int Psychogeriatr (2003) 0.82
Evaluation of the Effects od Severe Depression on Global Cognitive Function and Memory. CNS Spectr (2010) 0.81
Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease. J Geriatr Psychiatry Neurol (2003) 0.80
Atherosclerosis risk factors in American Indians with Alzheimer disease: preliminary findings. Alzheimer Dis Assoc Disord (2008) 0.79
Caregivers' perceptions of dementia patients' functional ability. Am J Alzheimers Dis Other Demen (2006) 0.79
Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly. Neuroepidemiology (2004) 0.79
Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry (2009) 0.79
Neuromics and neurological disease. Arch Neurol (2008) 0.79
Relationship between serum homocysteine levels and depressive symptoms: the Cooper Center Longitudinal Study. J Clin Psychiatry (2012) 0.78
Caregiver attribution and resentment in dementia care. Am J Alzheimers Dis Other Demen (2003) 0.78
Brain MRI, apoliprotein E genotype, and plasma homocysteine in American Indian Alzheimer disease patients and Indian controls. Curr Alzheimer Res (2009) 0.78
Mitochondrial therapy for Parkinson disease. Arch Neurol (2002) 0.78
Executive functioning and the metabolic syndrome: a project FRONTIER study. Arch Clin Neuropsychol (2013) 0.78
Donepezil effects on hippocampal and prefrontal functional connectivity in Alzheimer's disease: preliminary report. J Alzheimers Dis (2012) 0.77
Single neuropsychological test scores associated with rate of cognitive decline in early Alzheimer disease. Clin Neuropsychol (2014) 0.77
Increased risk for heterozygotes in recessive Parkinson disease. Arch Neurol (2006) 0.77
Progranulin and tau gene mutations both as cause for dementia: 17q21 finally defined. Arch Neurol (2007) 0.77
LDL phenotype in subjects with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis (2013) 0.77
Treating Alzheimer disease: Time matters. Arch Neurol (2006) 0.76
A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry (2003) 0.76
New presenilin 1 mutation with Alzheimer disease and Lewy bodies. Arch Neurol (2005) 0.76
Explaining the cause of the amyloid burden in Alzheimer disease. Arch Neurol (2002) 0.76
Plasma 24S hydroxycholesterol response to statins in Alzheimer's disease patients: effects of gender, CYP46, and ApoE polymorphisms. J Mol Neurosci (2007) 0.76
Metal chelation therapy for Alzheimer disease. Arch Neurol (2003) 0.76
Urinary albumin to creatinine ratio as potential biomarker for cerebral microvascular disease. Curr Neurovasc Res (2014) 0.75
Genes for movement. Arch Neurol (2004) 0.75
Measuring QOL in dementia. Int Psychogeriatr (2006) 0.75
Impact of an activities-based adult dementia care program. Neuropsychiatr Dis Treat (2005) 0.75
Pain 2003. Arch Neurol (2003) 0.75
Time and memory. Arch Neurol (2002) 0.75
Genes for movement. Arch Neurol (2004) 0.75
Positive potential of fetal nigral implants for Parkinson disease. Arch Neurol (2004) 0.75
Reexamining therapist self-disclosure. Psychiatr Serv (2002) 0.75
Is routine testing of vitamin B12 cost-effective in workup for cognitive impairment? Am Fam Physician (2012) 0.75
A simple method to rule out dementia with temporal orientation. Alzheimers Dement (2007) 0.75